| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | Chief Development Officer | Common Stock | 127,665 | $541,299 | $4.24 | 31 Jan 2026 | Direct |
| Atea Pharmaceuticals, Inc. | Chief Development Officer | Restricted Stock Units | 0 | $34,425 | $3.06 | 31 Jan 2026 | Direct |
| Atea Pharmaceuticals, Inc. | Chief Development Officer | Stock Option (Right to Buy) | 177,000 | 31 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2026 | 5 | -$59,937 | 4 | Chief Development Officer | 03 Feb 2026, 19:46 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2025 | 6 | -$43,250 | 4 | Chief Development Officer | 04 Feb 2025, 18:00 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2024 | 4 | -$53,913 | 4 | Chief Development Officer | 02 Feb 2024, 21:24 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2023 | 2 | $0 | 4 | Chief Development Officer | 02 Feb 2023, 17:28 |
| AVIR | Atea Pharmaceuticals, Inc. | 31 Jan 2022 | 1 | $0 | 4 | Chief Development Officer | 02 Feb 2022, 16:15 |